Galapagos NV announced they completed the recruitment phase for patients with rheumatoid arthritis to enroll their Darwin Phase 2B program evaluating GLPG0634 (filgotinib) as a monotherapy for rheumatoid arthritis. GLPG0634 is a selective inhibitor of JAK1, a key factor in the JAK-STAT ... Read more